Billionaires Are RUSHING To Buy THIS Biotech Stock NOW! COGT Set For 2x Gains?
Did you know some billionaires are quietly betting big on a biotech stock with multibagger potential? Cogent Biosciences, ticker COGT, is making waves, having just released an earnings report showcasing significant regulatory momentum following three positive pivotal trials for its lead candidate, bezuclastinib. This clinical-stage company has already submitted one NDA and plans more, supported by impressive trial data, including nearly doubling progression-free survival in GIST patients. Moreover, Cogent ended 2025 with nearly a billion dollars in cash, projecting operations funded into 2028, signaling strong financial health. For more surprising stock picks and investment strategies, subscribe to our channel today!
Tags/Hashtags: #cogt #investing #bezuclastinib #nda #gist #cogt
Leave a Reply